NCT03233308View on ClinicalTrials.gov

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

April 19, 2018

Study Completion Date

April 19, 2018

Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
DRUG

Netarsudil Ophthalmic Solution 0.02%

1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye

OTHER

Placebo Comparator

1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye

Trial Locations (2)

27710

Duke Eye Center, Durham

55905

Mayo Clinic, Rochester

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT03233308 - Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) | Biotech Hunter | Biotech Hunter